0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Other Articles |

CLINICAL EXCRETION OF BISMUTH AFTER ORAL ADMINISTRATION OF SOBISMINOL

P. J. HANZLIK, M.D.; A. J. LEHMAN, M.D., Ph.D.; A. P. RICHARDSON, M.D.; W. VAN WINKLE Jr., A.B.
Arch Derm Syphilol. 1937;36(4):708-724. doi:10.1001/archderm.1937.01480040025002.
Text Size: A A A
Published online

Pursuant to a preliminary report1 on sodium bismuthate soluble, now called sobisminol, this report presents complete clinical data on excretion. This is important in relation to the use of this bismuth compound in antisyphilitic treatment. The results obtained leave no doubt of a prompt and well sustained absorption of bismuth. Continued daily medication sustains concentrations of bismuth in the blood and tissues comparable to those resulting from intramuscular injections. Effects, in general, indicate that oral administration of sobisminol bids fair to be a practical therapeutic measure.

PROCEDURE  Twelve complete observations were made on seven different persons, i. e., on four healthy male research workers, two male patients and one female patient. Study of the excretion of bismuth in the urine was made with administration of small and of large single doses of sobisminol, of divided weekly doses and of daily doses for two weeks, with both soluble and insoluble

Topics

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();